National Comprehensive Cancer Network



About NCCN

NCCN Physicians Present Studies Funded by the NCCN Oncology Research Program at ASCO

By Megan Martin, Communications Manager

Clinical research funded through the NCCN Oncology Research Program (ORP) was the focus of several poster presentations at the 2010 ASCO Annual Meeting. The NCCN ORP is organized to obtain funding to support scientifically meritorious research projects at the NCCN Member Institutions, which explore new venues of clinical investigation that answer important scientific questions. To date, the NCCN ORP has provided more than $21 million in research funding to investigators at NCCN Member Institutions. Researchers from NCCN Member Institutions presented the following posters detailing NCCN-funded studies at ASCO.

General Poster Sessions:

Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC)
– Presented by Nikhil Khushalani, MD, Roswell Park Cancer Institute

A Phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC)
– Presented by Andrew Ko, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Trials in Progress Poster Sessions:

Phase II Trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies
– Presented by Gregory Otterson, MD, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
– Presented by Jasgit Sachdev, MD, University of Tennessee Cancer Institute

Phase I study of bendamustine and fractionated stereotactic radiotherapy (FSRT) in patients with one to three brain metastases from solid malignancies
– Presented by John Grecula, MD, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)
– Presented by Robin Katie Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab
– Presented by Maha Hussain, MD, University of Michigan Comprehensive Cancer Center

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved